The XII National Congress of Cardiologists of Ukraine took place on September 21-33, 2011 in Kiev. The congress was carried out at organizational support of the National Academy of Sciences of Ukraine, the National Academy of Medical Sciences of Ukraine,

The XII National Congress of Cardiologists of Ukraine took place on September 21-33, 2011 in Kiev. The congress was carried out at organizational support of the National Academy of Sciences of Ukraine, the National Academy of Medical Sciences of Ukraine, the Ministry of Healthcare of Ukraine, the Association of Cardiologists of Ukraine and the National Scientific Centre “Institute of Cardiology named after N.D. Strazheska” of the National Academy of Medical Sciences of Ukraine.

 The XII National Congress of Cardiologists of Ukraine is a double anniversary, as it is in 2011 the Institute of Cardiology named after Academician Strazheska is 75 years old, and its founder, scientist Nikolay Dmitriyevich Strazheska was born 135 years ago. The program of the Congress was really full of events; a number of urgent issues of cardiology were considered during the Congress. More than 1500 leading scientists in the field of cardiology from all over Ukraine and foreign representatives of this sphere from Russia, Germany, Czech Republic, Slovenia, the USA, Italy, England and Japan gathered to discuss scientific and practical problems and prospects of cardiology development, as well as new achievements and researches, obtained during the year.

Within the congress, the company Ananta Medicare took part in the pharmaceutical exhibition, where it presented a stand with information about its new preparation Azi-Ator, as well as Company’s preparations – Flamogrel (clopidogrel), Cardipril (ramipril) and Limistin (atorvastatin). The preparation Azi-Ator provides double protection owing to the presence of two active substances: atorvastatin and ezetimib (the agent that selectively inhibits cholesterol absorption in the intestine). Hypolipidemic effectiveness of the combination of atorvastatin 10 mg and ezetimib 10 mg is similar to those of atorvastatin in the dose of 80 mg. In numerous clinical studies it is proved that the therapy with ezetimib in combination with atorvastatin is well tolerated by patients; its safety is comparable to that of monotherapy with atorvastatin. 

 
All employees of the company Ananta Medicare are sure, that the appearance of most modern and highly efficient hypolipidemic agent – Azi-Ator preparation – in doctor’s arsenal will help to improve significantly the quality of treatment and quality of life of patients with cardiovascular diseases.

Together we are stronger!